Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Medicinal mushrooms have demonstrated various pharmacological properties due to the numerous compounds in their mycelial structures, that can act in a synergistic or non-synergistic manner to treat different diseases and conditions. In this study, the Auricularia fuscosuccinea (AF), recognized for its high fiber content, protein, amino acids, low glucose levels and no toxic effects, was administered to rats with Type 2 Diabetic Mellitus (T2DM) and diabetic kidney disease (DKD) in order to evaluate its impact on renal function. Objective: evaluate the renoprotective effect of the AF in DKD in rats.
Adult Wistar rats were divided into three groups: Control- vehicle (0.1M citrate buffer, 60mg/kg, i.p.); T2DM - T2DM induction (nicotinamide, 100mg/kg, intraperitoneal, i.p. + streptozotocin, diluted in 0.1M citrate buffer, 60mg/kg, i.p., once). and T2DM+AF - Auricularia fuscosuccinea (AF, 100mg/kg, diluted in 1mL of drinking water, orally, once a day, 30 days) in T2DM rats. Evaluation of renal function by serum creatinine and inulin clearance (Clin) and oxidative profile by urinary peroxides (FOX), thiols and catalase were evaluated.
The treated group, T2DM+AF, presented a reduction in serum creatinine (0.29±0.03 vs 1.02±0,30, p<0.05) and an increased inulin clearance (0.79±0.50 vs 0.30±0.03, p<0,05) compared with the T2DM group. Also, the oxidative profile of the T2DM+AF group showed a reduction in urinary peroxides (0.11±0.20 vs 12.0±1.8nmol/g creat, p<0.05) and elevation in the thiol (18.9±6.0 vs 1.6±0.6 nmol/g, p<0.05) and catalase levels (6.72±1.39 vs 0.40±0.01 umg/ml, p<0.05) compared with T2DM group.
This is the first study to point out the therapeutical properties of the amazonian mushroom Auricularia fuscosuccinea (AF). The oral administration of AF showed renoprotective effects in renal function and attenuation of the oxidative damage, confirming its antioxidant properties in the DKD. Our findings demonstrate that consuming AF daily shows additional beneficial effects in the treatment, protecting renal function from the insults of the T2DM. Further studies are needed to assess long-term outcomes regarding its new product.
